- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04881630
Mobil beredskapshåndtering for røykeslutt (P3)
Mobil beredskapshåndtering for røykeslutt blant sosioøkonomisk vanskeligstilte voksne
The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The primary purpose of the proposed project is to evaluate an automated smartphone-based CM approach that will allow socioeconomically disadvantaged adults to earn financial incentives for smoking cessation without requiring in-person attendance for abstinence verification. The investigators have combined technologies: 1) low-cost carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to verify the identity of participants while they provide a breath sample, and 3) remote and automated delivery of incentives to a credit card triggered by biochemical confirmation of self-reported smoking abstinence. This CM approach will be evaluated in a randomized controlled trial of 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to telephone counseling plus nicotine replacement therapy (standard care [SC]) or SC plus a 12-week smartphone-based financial incentives intervention (CM). Participants will be followed for 26 weeks after a scheduled quit attempt, which is 14 weeks after incentives have ended. Cost-effectiveness will be evaluated to inform policy and health care decisions. Potential CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement will be identified to optimize future versions of the intervention. The specific aims are: 1) to evaluate the impact of an automated, mobile phone-based CM approach relative to SC on smoking cessation among socioeconomically disadvantaged adults, 2) to compare the cost-effectiveness of two smoking cessation interventions (CM vs. SC), and 3) to identify mobile CM treatment mechanisms such as motivation to quit, self-efficacy for quitting, and treatment engagement/adherence. The proposed study will evaluate an intervention approach that increases the reach of a potentially effective and cost-effective smoking cessation intervention for socioeconomically disadvantaged smokers. This proposed study is also going to be conducting recruitment nationwide.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Oklahoma
-
Oklahoma City, OK, Oklahoma, Forente stater, 73104
- TSET Health Promotion Research Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- report an annual household income of <200% of the federal poverty threshold (i.e., low-income)
- earn a score ≥4 on the REALM indicating >6th grade English literacy level (i.e., a 7th grade reading level is necessary to complete assessments)
- are willing to quit smoking 7-14 days after enrollment
- are ≥ 18 years of age
- currently smoke ≥ 5 cigarettes per day
- have a CO level of >6 ppm
- are willing to abstain from smoking cannabis and other combustible tobacco products (they raise CO levels and mask cigarette abstinence)
- have no contraindications for NRT
- Provide a copy/photo of driver's license or other documentation as proof of identity and U.S. residence
Exclusion Criteria
1) do not meet the specified inclusion criteria
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Standard Care (SC)
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy. |
Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges) |
|
Eksperimentell: Contingency Management (CM)
CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence. |
Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges) Financial incentives contingent upon smoking abstinence |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 26 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit. |
26 weeks post-quit-date
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cost-effectiveness
Tidsramme: 26 weeks post-quit-date
|
The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs. |
26 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 12 week post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date. |
12 week post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 8 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date. |
8 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 4 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date. |
4 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)
Tidsramme: 26 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date. |
26 weeks post-quit-date
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Darla E. Kendzor, PhD, University of Oklahoma
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 12881Ph3
- R01CA251451 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified data will be made available to investigators upon request, after publication of the primary study findings, and with a data-sharing agreement that specifies the investigator(s) will 1) use the data only for research purposes and not to identify any individual participant, 2) store the data on a secure device (e.g., encrypted, password-protected), and 3) destroy or return the data after completion of the analyses.
IPD-delingstidsramme
De-identified data will be made available to investigators upon request after publication of the primary study findings.
Tilgangskriterier for IPD-deling
Data sharing agreement
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .